Top gainers, as of 5:15 p.m.: SRPT +5.9% . REXX +5.1% . PE +4.6% . MHR +4.3% . NPSP +4.3% . Top losers, as of 5:15 p.m.: KING -21.1% . ARWR -11.9% . QNST -9.8% . CREE -6.3% . MYGN -5.1% . Post your comment!
NPS Pharmaceuticals Inc. (NASDAQ: NPSP ) Q2 2014 Results Earnings Conference Call August 06, 2014, 05 ..... Operator Good day, ladies and gentlemen, and welcome to the NPS Pharmaceuticals Second Quarter 2014 Financial Result Conference Call. My
NPS Pharmaceuticals ( NPSP -1.1% ) Q2 results : Revenues: $56.1M (+53.7%); Operating Expenses: $47.6M (+4.8%); Operating Income
The following audio is from a conference call that will begin on August 06, 2014 at 17:00 PM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now Complete Story »
NPS Pharmaceuticals (NASDAQ: NPSP ): Q2 EPS of $0.02 beats by $0.02 . Revenue of $56.13M (+53.8% Y/Y) beats by $3.07M . Press Release Post your comment!
ITMN , IXYS , JACK , KEG , KND , KW , LGP , LHCG , LNT , MBI , MCP , MG , MHLD , MNTX , MRIN , MTDR , MUSA , MWE , NBIX , NLY , NPSP , NRP , NVAX , NVTL , OILT , OSUR , PAA , PACD , PKT , PMT , PPO , PRI , PRU , PRXL , PTLA , QEP , RAIL , REG , RGP , RIG , RJET
Technology ( GTAT +5.7% ). Also included are Health Care names: Agios Pharmaceuticals ( AGIO -1.1% ), NPS Pharma ( NPSP +0.7% ), NuVasive ( NUVA -1.8% ), Synageva ( GEVA -1.6% ); Consumer Staples: Darling Ingredients ( DAR -0
By Alexander Maxwell : It can be very hard for investors to be able to keep track of all of the different events going on within the biotech world, with clinical trial results, and FDA decisions happening rather frequently. The purpose of this article is to hopefully make investor's lives a little
By Benjamin Livingston : NPS Pharmaceuticals (NASDAQ: NPSP ) is a biopharmaceutical that ..... With this strategy in mind, NPSP develops drugs that will, in ..... company has to offer. In addition, NPSP receives royalties from numerous
Pharmaceuticals International, Inc. (U.S. Shares) (2.19%), AstraZeneca PLC (ADR) (1.78%) and NPS Pharmaceuticals , Inc. (1.74%). There are no assurances that any Janus portfolio currently holds these securities or other